Voyager Therapeutics Prioritizes Pipeline and Reports Second Quarter 2022 Financial and Operating Results

Magenta Therapeutics Reports Second Quarter Financial Results and Recent Program Highlights

Voyager Therapeutics Presents New Data Demonstrating Novel Candidate Therapeutic Antibodies Reduced Tau Pathology in Multiple Preclinical Models

Nurix Therapeutics Announces Appointment of Eric Schlezinger, J.D. as Chief People Officer

Element Science Announces First Patient Save with Jewel Patch Wearable Cardioverter Defibrillator (P-WCD)